Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission

Am J Hematol. 2023 Feb;98(2):E35-E37. doi: 10.1002/ajh.26789. Epub 2022 Dec 11.

¹ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
² Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.
³ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁴ Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

No abstract available

Publication types